Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Large Decrease in Short Interest

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 254 shares, a decline of 84.2% from the November 30th total of 1,606 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 4,132 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 4,132 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are sold short.

Ascentage Pharma Group International Trading Up 5.2%

Shares of AAPG stock traded up $1.39 during mid-day trading on Wednesday, hitting $27.88. 868 shares of the stock were exchanged, compared to its average volume of 3,969. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. Ascentage Pharma Group International has a 52-week low of $16.50 and a 52-week high of $48.45. The firm has a fifty day moving average of $32.14 and a 200 day moving average of $36.82.

Analysts Set New Price Targets

Several brokerages have weighed in on AAPG. Piper Sandler started coverage on Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price target on the stock. Lucid Cap Mkts upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. BTIG Research began coverage on Ascentage Pharma Group International in a report on Monday, November 10th. They set a “buy” rating and a $50.00 target price on the stock. Truist Financial set a $51.00 price target on Ascentage Pharma Group International in a report on Monday, November 24th. Finally, Oppenheimer started coverage on Ascentage Pharma Group International in a research report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, Ascentage Pharma Group International currently has an average rating of “Buy” and an average price target of $48.50.

Institutional Trading of Ascentage Pharma Group International

Institutional investors and hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in Ascentage Pharma Group International during the third quarter worth $96,000. ABC Arbitrage SA acquired a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth $204,000. Chevy Chase Trust Holdings LLC purchased a new position in shares of Ascentage Pharma Group International during the 2nd quarter worth $227,000. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at about $383,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter valued at about $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.